IceCure Medical (ICCM) Net Income towards Common Stockholders (2020 - 2026)

IceCure Medical (ICCM) has 7 years of Net Income towards Common Stockholders data on file, last reported at $4.2 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 18.37% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $15.7 million, a 284.21% increase from a year earlier, with the FY2025 full-year figure at -$11.9 million, up 49.84% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $4.2 million, roughly flat from $4.2 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for ICCM reached as high as $4.4 million in Q1 2022 and fell as low as -$46.9 million in Q4 2023.
• Historically, Net Income towards Common Stockholders has averaged -$3.4 million across 5 years, with a median of $4.0 million in 2023.
• On a YoY basis, Net Income towards Common Stockholders climbed as much as 270.91% in 2022 and fell as far as 53.49% in 2022.
• Year by year, Net Income towards Common Stockholders stood at -$46.9 million in 2022, then declined by 0.12% to -$46.9 million in 2023, then jumped by 58.76% to -$19.3 million in 2024, then soared by 121.93% to $4.2 million in 2025, then rose by 0.09% to $4.2 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $4.2 million in Q1 2026, $4.2 million in Q4 2025, and $3.9 million in Q3 2025.